Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...
Jacobs Solutions CEO Bob Pragada joins 'Squawk Box' to discuss the building opportunities of life science facilities to meet ...
2d
Public News Service on MSNGLP-1 meds offer new hope for heart health amid weight-loss crazeThe GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...
Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results